Безопасность, иммуногенность и профилактическая эффективность вакцинных штаммов вируса гриппа А/Н5N1 с удаленными факторами патогенности: белками NS1 и PB1-F2
Диссертация
С помощью методов «обратной генетики» впервые были получены вакцинные штаммы с удаленной геномной последовательностью, кодирующей белок NS1 (delNSl), относящиеся к различным клайдам вируса гриппа A/H5N1. Впервые получены данные о способности H5N1 вакцинных штаммов к эффективному росту на культуре клеток Vero и их генетической стабильности при длительном пассировании. Получена новая информация… Читать ещё >
Список литературы
- Александрова Г., Климов А. Живая вакцина против гриппа. СПб., 1994,1. Из д. «Наука» .-151с.
- Гендон Ю. 3. Живая холодоадаптированная гриппозная вакцина: современное состояние // Вопр. вирусол. 2011. — № 1. -С. 4−17.
- Гендон Ю. Преимущества и недостатки инактивированной и живой вакцинпротив гриппа // Вопр. вирусол. -2004. № 4. — С. 4−12.
- Григорьева Е., Дешева Ю., Донина С. и др. Сравнительная оценкабезвредности, иммуногенной активности и профилактической эффективности взрослого и детского вариантов живой гриппозной вакцины у школьников 7−14 лет // Вопр. вирусол. 2002. — № 4. — С. 24−27.
- Ершов Ф.И., Киселев О. И. Интерфероны и их индукторы (от молекулы долекарств). М., 2005. — Изд. гр. «ГОЭТАР-Медиа». — 368 с.
- Жданов В., Александрова Г., Гендон Ю. Живые гриппозные вакцины в
- СССР: разработка, изучение и практическое использование // Жури, микробиол. 1986. — № 7. — С. 3- 13.
- Каверин Н.В., Смирнов Ю. А. Межвидовая трансмиссия вирусов гриппа, А ипроблема пандемий // Вопр вирус. 2003. — № 3. — С. 4−10.
- Киселев О. И., Блинов В. М., Писарева М. М. и др. Изоляты вируса гриппаподтипа Н5№, выделенные от домашней птицы в Курганской области в 2005 году: молекулярно-генетическая характеристика // Мол. биология. -2008. Т.42. — № 1. — С. 78−87.
- Львов Д. Популяционные взаимодействия в биологической системе: вирусгриппа А-дикие и домашние животные- человек // Журн. микробиол. -2006. -№ 3. С. 96−100.
- Львов Д. К., Щелканов М. Ю., Власов Н. А. и др. Первый прорыв новогодля России генотипа 2.3.2 высоковирулентного вируса гриппа А/Н5.П на Дальнем Востоке // Вопр. вирусол. 2008. — № 5. — С. 4−9.
- Найхин А.Н., Рекстин А. Р., Донина С. А., и др. Иммуномодулирующийэффект липринола у людей, вакцинированных живой гриппозной вакциной // Медицинский Академический журнал. 2003. — Т.З. — № 4. — С. 60−65.
- Abramowicz М. FluMist: an intranasal live influenza vaccine // Med Lett Drugs.2003. Vol. 45. — P. 65−66.
- Alexandrova G., Budilovsky G., Koval T. et al. Study of live recombinant coldadapted influenza bivalent vaccine of type A for use in children: an epidemiological control trial // Vaccine. 1986. — Vol.4. -P. 114−148.
- Aragon Т., de la Luna S., Novoa I. et al. Eukaryotic translation initiation factor 4GI is a cellular target for NS1 protein, a translational activator of influenza virus // Mol Cell Biol. 2000. — Vol. 20. — P. 6259−6268.
- Auewarakul P., Suptawiwat O., Kongchanagul A. An avian influenza H5N1 virus that binds to a human-type receptor // J Virol. 2007. — Vol.81(18). — P. 99 509 955.
- Baigent S., McCauley J. Influenza type A in humans, mammals and birds: determinants of virus virulence, host-range and interspecies transmission // Bioessays. 2003. — Vol.25(7). -P. 657−671.
- Balachandran S., Kim C., Yeh W. et al. Activation of the dsRNA-dependentprotein kinase, PKR, induces apoptosis through FADD-mediated death signaling // EMBO J. 1998. — Vol. 17(23). — P. 6888−902.
- Banchereau J., Steinman R.M. Dendritic cells and the control of immunity //
- Nature. 1998. — Vol.392(6673). — P. 245−252.
- Basler C.F. and Aguilar P.V. Progress in identifying virulence determinants of the1918 HINland the Southeast Asian H5N1 influenza A viruses // Antiviral Res. 2008. Vol. 79(3). — P. 166−178.
- Baudin F., Bach C., Cusack S. and Ruigrok R.W. Structure of influenza virus
- RNP. I. Influenza virus nucleoprotein melts secondary structure in panhandle RNA and exposes the bases to the solvent // Embo J. 1994. — Vol.13. — P. 31 583 165.
- Belshe R.B., Gruber W., Mendelman P et al. Correlates of immune protectioninduced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine // J Infect Dis. 2000. — Vol. 181(3). — P. 1133−1137.
- Bergmann M., Garcia-Sastre A., Carnero E. et al. Influenza virus NS1 protein counteracts PKR-mediated inhibition of replication // In J Virol. 2000. — P. 6203.
- Bornholdt Z.A., Prasad B. X-ray structure of influenza virus NS1 effector domain // Nat Struct Mol Biol. 2006. — Vol. 13(6). — P. 559−560.
- Bresson J.L., Perronne C., Launay O. and Gerdil C. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial // Lancet. 2006. — Vol. 367. — P. 1657−1664.
- Bright R., Carter D., Crevar C. et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle //PLoS One. 2008. — Vol.3(l). — e. 1501.
- Bright R.A., Medina M.J., Xu X. and Perez-Oronoz G. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern // Lancet. 2005. — Vol.366. — P. 1175−1181.
- Brown L, Capua I., Cattoli G et al. Continuing progress towards a unifiednomenclature for the highly pathogenic H5N1 avian influenza viruses: divergence of clade 2.2 virus // Influenza Other Resp. Viruses. 2009. -Vol.3(2). — P. 59−62.
- Brownlee G.G., Fodor E. The predicted antigenicity of the haemagglutinin of the1918 Spanish influenza pandemic suggests an avian origin // Philos Trans R Soc Lond B Biol Sci. 2001. — Vol. 356. — P. 1871−1876.
- Brownlee G.G., Sharps J. The RNA polymerase of influenza a virus is stabilized by interaction with its viral RNA promoter // J Virol. 2002. — Vol.76(14). — P. 7103−7113.
- Carrasco M., Amorim M., Digard P. Lipid raft-dependent targeting of the influenza A virus nucleoprotein to the apical plasma membrane // Traffic. -2004. Vol.5(12). — P. 979−992.
- Castelli J., Wood K.A., Youle R.J. The 2−5A system in viral infection and apoptosis // Biomed Pharmacother. 1998. — Vol.52(9). — P. 386−390.
- Chen H., Li Y., Li Z., Shi J. Properties and dissemination of H5N1 virusesisolated during an influenza outbreak in migratory waterfowl in western China // J Virol. 2006. — Vol.80. — P. 5976−5983 (6).
- Chen H., Smith G.J., Li K.S., et al. Establishment of multiple sublineages of
- H5N1 influenza virus in Asia: implications for pandemic control // Proc Natl Acad Sci USA.- 2006. Vol. (8). — P. 2845−2850 (a).
- Chen W., Calvo P., Malide D. et al. A novel influenza A virus mitochondrialprotein that induces cell death //Nat Med. 2001. — Vol.7(12). — P. 1306−1312.
- Chen Z. and Krug R.M. Selective nuclear export of viral mRNAs in influenzavirus infected cells // Trends Microbiol. 2000. — Vol. 8. — P. 376−383.
- Chen Z., Li Y. and Krug R.M. Influenza A virus NS1 protein targets poly (A)binding protein II of the cellular 3'-end processing machinery // Embo J. 1999. -Vol. 18.-P. 2273−2283.
- Cheng X., Eisenbraun M., Xu Q. H5N1 vaccine-specific B cell responses inferrets primed with live attenuated seasonal influenza vaccines // PLoS ONE. -2009. Vol.4(2). — e.4336.
- Clifford M., Twigg J., Upton C. Evidence for a novel gene associated with humaninfluenza A viruses // Virol J. 2009. — Vol.6. — P. 198.
- Coleman J.R.The PB1-F2 protein of Influenza A virus: increasing pathogenicityby disrupting alveolar macrophages // Virol J. 2007. — Vol.4. — P. 9.
- Conenello G.M., Palese P. Influenza A virus PB1-F2: a small protein with a bigpunch // Cell Host Microbe. 2007. — Vol.2(4). — P. 207−209.
- Cox N., Subbarao K. Influenza // Lancet. 1999. — Vol.354(9186). — P. 12 771 282.
- Cox R.J., Brokstad K.A. and Ogra P. Influenza virus: immunity and vaccinationstrategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines // Scand J Immunol. 2004. — Vol. 59. — P. 1−15.
- Curran M., Leroux-Roels I. Inactivated split-virion seasonal influenza vaccine
- Fluarix): a review of its use in the prevention of seasonal influenza in adults and the elderly // Drugs. 2010. — Vol.70(12). — P. 1519−1543.
- De Filette M., Ramne A., Birkett A., Lycke N. The universal influenza vaccine
- M2e-HBc administered intranasally in combination with the adjuvant CTA1 -DD provides complete protection // Vaccine. 2006. — Vol. 24. — P. 544−551.50. de Jong M., Simmons C., Thanh T.T. et al. Fatal outcome of human influenza A
- Desheva J., Lu X.H., Rekstin A.R. et al. Characterization of an influenza A
- H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential // Vaccine. -2006. Vol.24. — P. 6859−6866.
- Ding H., Tsai C., Gutierrez R. et al. Superior neutralizing antibody response andprotection in mice vaccinated with heterologous DNA prime and virus like particle boost against HPAI H5N1 virus // PLoS One. 2011. — Vol.6(l). -e.16 563.
- Egorov A., Brandt, S., Sereinig S et al. Transfectant influenza A viruses with longdeletions in the NS1 protein grow efficiently in Vero cells // J Virol. 1998. -Vol. 72. — P. 6437−6441.
- Ehrlich H., Muller M., Oh H.M. et al. A clinical trial of a whole-virus H5N1vaccine derived from cell culture // N Engl J Med. 2008. — Vol.358. — P. 25 732 582.
- Enami M. and Palese P. High-efficiency formation of influenza virustransfectants//J Virol. 1991. — Vol.65(5). — P. 2711−2713.
- Falcon A.M., Fernandez-Sesma A., Nakaya Y. et al. Attenuation andimmunogenicity in mice of temperature-sensitive influenza viruses expressing truncated NS1 proteins // J Gen Virol. 2005. — Vol.86. — P. 2817−2821.
- Fan S., Gao Y., Shinya K. et al. Immunogenicity and protective efficacy of a liveattenuated H5N1 vaccine in nonhuman primates // PLoS Pathog. 2009. -Vol.5(5). — e. 1 000 409.
- Fan J., Liang X., Horton M.S., Perry H.C. Preclinical study of influenza virus A
- M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys // Vaccine. 2004. — Vol. 22. — P. 2993−3003.
- Ferko B., Stasakova J., Romanova J. et al. Immunogenicity and protectionefficacy of replication-deficient influenza A viruses with altered NS1 genes // J Virol. 2004. — Vol. 78. — P. 13 037−13 045.
- Fernandez-Sesma A. The influenza virus NS1 protein: inhibitor of innate andadaptive immunity // Infect Disord Drug Targets. 2007. — Vol.7(4). — P. 336 343.
- Fernandez-Sesma A., Marukian S., Ebersole B. et al. Influenza virus evadesinnate and adaptive immunity via the NS1 protein // J Virol. 2006. -Vol.80(13). — P. 6295−6304.
- Fodor E., Devenish L., Engelhardt O. G. et al. Rescue of influenza A virus fromrecombinant DNA // J Virol. 1999. — Vol. 73. — P. 9679−9682.
- Gaidet N., Dodman T., Caron A. Avian influenza viruses in water birds, Africa //
- Emerg Infect Dis. 2007. — Vol. 13(4). — P. 626−629.
- Gambotto A., Barratt-Boyes S., de Jong M., Neumann G., Kawaoka Y. Human infection with highly pathogenic H5N1 influenza virus // Lancet. 2008. -Vol.371(9622). — P. 1464−1475.
- Garcia-Sastre A., Egorov A., Matassov D. et al. Influenza A virus lacking the
- NS1 gene replicates in interferon-deficient systems // Virology. 1998. — Vol. 252. — P. 324−330.
- Gocnikova H., Russ G. Influenza a virus PB1-F2 protein // Acta Virol. 2007.1. Vol.51(2). P. 101−108.
- Goji N., Nolan C., Hill H. et al. Immune responses of healthy subjects to a singledose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant // J Infect Dis. 2008. -Vol. 198(5). — P. 635−641.
- Gorse G., Belshe R., Munn N.J. Superiority of live attenuated compared withinactivated influenza A virus vaccines in older, chronically ill adults // Chest. -1991. Vol. 100(4). — P. 977−984.
- Govorkova E.A., Webby R.J., Humberd J. Immunization with reverse-geneticsproduced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge // J Infect Dis.- 2006. Vol. 194(2). — P. 159−167.
- Greenspan D., Palese P. and Krystal M. Two nuclear location signals in theinfluenza virus NS1 nonstructural protein // J Virol. 1988. — Vol. 62. — P. 3020−3026.
- Gruber W.C. The role of live influenza vaccines in children // Vaccine. 2002.
- Vol.20 Suppl 2. P. S66−73.
- Guan Y., Peiris J.S., Lipatov A.S. and Ellis T.M. Emergence of multiplegenotypes of H5N1 avian influenza viruses in Hong Kong SAR // Proc Natl Acad Sci USA.- 2002. Vol.99. — P. 8950−8955.
- Hale B.G., Randall R., Ortin J. and Jackson D. The multifunctional NS1 proteinof influenza A viruses // J Gen Virol. 2008. — Vol.89. — P. 2359−2376.
- Hasegawa H., Ichinohe T., Tamura S. and Kurata T. Development of a mucosalvaccine for influenza viruses: preparation for a potential influenza pandemic // Expert Rev Vaccines. 2007. — Vol.6(2). — P. 193−201.
- Hatta M., Kawaoka Y. The continued pandemic threat posed by avian influenzaviruses in Hong Kong // Trends Microbiol. 2002. — Vol.10. — P. 340−344.
- Hauge S., Madhun A., Cox R. and Haaheim L.R. Quality and kinetics of theantibody response in mice after three different low-dose influenza virus vaccination strategies // Clin Vaccine Immunol. 2007. — Vol. 14(8). — P. 978 983.
- Hayman A., Comely S., Lackenby A. et al. NS1 proteins of avian influenza Aviruses can act as antagonists of the human alpha/beta interferon response // J Virol. 2007. — Vol.81(5). — P. 2318−2327.
- Hinshaw V., Olsen C.W., Dybdahl-Sissoko N. and Evans D. Apoptosis: amechanism of cell killing by influenza A and B viruses // J Virol. 1994. -Vol.68(6). — P. 3667−3673.
- Hoelscher M.A., Garg S., Bangari D.S. Development of adenoviral-vector-basedpandemic influenza vaccine against antigenetically distinct human H5N1 strains in mice // Lancet. 2006. — Vol.367(9509). — P. 475−481.
- Hoffmann E., Webster R.G. Unidirectional RNA polymerase I-polymerase IItranscription system for the generation of influenza A virus from eight plasmids // J Gen Virol. 2000. — Vol.81. — P. 2843−2847.
- Honda K., Yanai H., Takaoka A. and Taniguchi T. Regulation of the type I IFNinduction: a current view //Int Immunol. -2005. Vol. 17(11). — P. 1367−1378.
- Horimoto T., Takada A., Fujii K. et al. The development and characterization of
- H5 influenza virus vaccines derived from a 2003 human isolate // Vaccine. -2006. Vol.24(17). — P. 3669−3676.
- Hsu M. T., Parvin J. D., Gupta S., Krystal M., Palese P. Genomic RNAs ofinfluenza viruses are held in a circular conformation in virions and in infected cells by a terminal panhandle // Proc Natl Acad Sci USA.- 1987. Vol. 84. — P. 8140−8144.
- Jegerlehner A., Schmitz N., Storni T., Bachmann M.F. Influenza A vaccine basedon the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity // J Immunol. 2004. — Vol.172. — P. 5598−5605.
- Kalia V., Sarkar S., Gourley T., Rouse B., Ahmed R. Differentiation of memory
- B and T cells // Curr Opin Immunol. 2006. — Vol. 18(3). — P. 255−264.
- Karron R.A., Talaat K., Luke C. et al. Evaluation of two live attenuated coldadapted H5N1 influenza virus vaccines in healthy adults // Vaccine. 2009. -Vol.27(36). — P. 4953−4960.
- Katz J.M., Lim W., Bridges C.B. and Rowe T. Antibody response in individualsinfected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts // J Infect Dis. 1999. — Vol. 180. -P. 1763−1770.
- Kawaguchi A., Naito T., Nagata K. Involvement of influenza virus PA subunit inassembly of functional RNA polymerase complexes // J Virol. 2005. -Vol.79(2). — P. 732−744.
- Kendal A.P. Cold-adapted live attenuated influenza vaccines developed in
- Russia: can they contribute to meeting the needs for influenza control in other countries? // Eur J Epidemiol. 1997. — Vol. 13(5). — P. 591−609.
- Kistner O., Howard M., Spruth M. et al. Cell culture (Vero) derived whole virus
- H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses // Vaccine. 2007. — Vol.25(32). — P. 6028−6036.
- Kittel C., Ferko B., Kurz M. et al. Generation of an influenza A virus vectorexpressing biologically active human interleukin-2 from the NS gene segment // J Virol. 2005. — Vol.79(16). — P. 10 672−10 677.
- Kochs G., Garcia-Sastre A., Martinez-Sobrido L. Multiple anti-interferon actionsof the influenza A virus NS1 protein // J Virol. 2007. — Vol.81(13). — P. 70 117 021.
- Krug R. M., Yuan W., Noah D. L. and Latham A. G. Intracellular warfarebetween human influenza viruses and human cells: the roles of the viral NS1 protein//Virology. 2003. — Vol. 309. — P. 181−189.
- Kuiken T., Rimmelzwaan G., van Riel D., van Amerongen G. Avian H5N1influenza in cats // Science. 2004. — Vol. 306. — P. 241.
- Lamb R. A. and Krug R. M. Orthomyxoviridae: the viruses and their replication //
- Fields Virology. 2001. — Fourth Ed, Lippincott Williams & Wilkins, Philadelphia. — P. 1487−1532.
- Lambkin R., Oxford J., Bossuyt S. et al. Strong local and systemic protectiveimmunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine // Vaccine. 2004. — Vol.22(31−32). — P. 4390−4396.
- Le Goffic R., Bouguyon E., Chevalier C. et al. Influenza A virus protein PB1-F2exacerbates IFN-beta expression of human respiratory epithelial cells // J Immunol. 2010. — Vol. l85(8). — P. 4812−4823.
- Leroux-Roels I., Bernhard R., Gerard P. et al. Broad Clade 2 cross-reactiveimmunity induced by an adjuvanted clade 1 rH5Nl pandemic influenza vaccine // PLoS One. 2008. — Vol.3(2). — e. 1665.
- Levine M.M. Can needle-free administration of vaccines become the norm inglobal immunization? // Nat Med. 2003. — Vol.9(l). — P. 99−103.
- Li S., Liu C., Klimov A. et al. Recombinant influenza A virus vaccines for thepathogenic human A/Hong Kong/97 (H5N1) viruses // J Infect Dis. 1999. -Vol. 179(5). — P. 1132−1138.
- Li Y., Chen Z. Y., Wang W. et al. The 3'-end-processing factor CPSF is requiredfor the splicing of single-intron pre-mRNAs in vivo // Rna. 2001. — Vol. 7. — P. 920−931.
- Li Y., Yamakita Y. and Krug R. M. Regulation of a nuclear export signal by anadjacent inhibitory sequence: the effector domain of the influenza virus NS1 protein // Proc Natl Acad Sci USA.- 1998. Vol. 95. — P. 4864−4869.
- Li Z., Song D., Zhang H. et al. Improved Humoral Immunity Against
- Tuberculosis ESAT-6 Antigen by Chimeric DNA Prime and Protein Boost Strategy // DNA Cell Biol. 2006b. — Vol. 25. — P. 25−30.
- Lin C., Holland R. Jr., Donofrio J. et al. Caspase activation in equine influenzavirus induced apoptotic cell death // Vet Microbiol. 2002. — Vol.84(4). — P. 357 365.
- Lin D., Lan J., Zhang Z. Structure and function of the NS1 protein of influenza Avirus // Acta Biochim Biophys Sin (Shanghai). 2007, — Vol.39(3). — P. 155−162.
- Lipatov A.S., Evseenko V.A., Yen H.L. Influenza (H5N1) viruses in poultry, Russian Federation, 2005−2006 // Emerg Infect Dis. 2007. — Vol. 13(4). — P. 539−546.
- Lowen A. and Palese P. Influenza virus transmission: basic science andimplications for the use of antiviral drugs during a pandemic // Infect Disord Drug Targets. 2007. — Vol.7. — P. 318−328.
- Lu J., Long J., Jia L. et al. Reassortment and modification of hemagglutinincleavage motif of avian/WSN influenza viruses generated by reverse genetics that correlate with attenuation // Acta Virol. 2006. — Vol.50(4). — P. 243−249.
- Lu Y., Wambach M., Katze M. G., Krug R. M. Binding of the influenza virus
- NS1 protein to double-stranded RNA inhibits the activation of the protein kinase that phosphorylates the elF-2 translation initiation factor // Virology. 1995. -Vol. 214. -P. 222−228.
- Lu X., Edwards L., Desheva J. et al. Cross-protective immunity in mice inducedby live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses // Vaccine. 2006. — Vol.24. — P. 6588−6593.
- Luytjes W., Krystal M., Enami M., Pavin J. D. and Palese P. Amplification, expression, and packaging of foreign gene by influenza virus // Cell. 1989. -Vol. 59. -P. 1107−1113.
- Maines T., Szretter K., Perrone L. Pathogenesis of emerging avian influenzaviruses in mammals and the host innate immune response // Immunol Rev. -2008. Vol.225(l). — P. 68−84.
- Matrosovich M., Tuzikov A., Bovin N. et al. Early alterations of the receptorbinding properties of HI, H2, and H3 avian influenza virus hemagglutinins after their introduction into mammals // J Virol. 2000. — Vol.74(18). — P. 8502−8512.
- Mazur I., Anhlan D., Mitzner D. et al. The proapoptotic influenza A virus protein
- PB1-F2 regulates viral polymerase activity by interaction with the PB1 protein // Cell Microbiol. 2008. — Vol. 10(5). — P. 1140−1152.
- McAuley J., Hornung F., Boyd K. et al. Expression of the 1918 influenza A virus
- PB1-F2 enhances the pathogenesis of viral and secondary bacterial pneumonia // Cell Host Microbe. 2007. — Vol.2(4). — P. 240−249.
- Mellman I. and Steinman R.M. Dendritic cells: specialized and regulated antigenprocessing machines // Cell. 2001. — Vol. 106(3). — P. 255−258.
- Miyaki C., Quintilio W., Miyaji E., Botosso V., Kubrusly F., Santos F., Iourtov
- D., Higashi H., Raw I. Production of H5N1 (NIBRG-14) inactivated whole virus and split virion influenza vaccines and analysis of immunogenicity in mice using different adjuvant formulations // Vaccine. 2010. — Vol.28(13). — P. 25 052 509.
- Morris S., Price G., Barnett J. et al. Role of neuraminidase in influenza virusinduced apoptosis // J Gen Virol. 1999. — Vol.80. — P. 137−146.
- Mutsch M., Zhou W., Rhodes P. et al. Use of the inactivated intranasal influenzavaccine and the risk of Bell’s palsy in Switzerland // N Engl J Med. 2004,-Vol.350(9). — P. 896−903.
- Nemeroff M. E., Barabino S. M., Li Y., Keller W. and Krug R. M. Influenza virus
- NS1 protein interacts with the cellular 30 kDa subunit of CPSF and inhibits 3'end formation of cellular pre-mRNAs // Cell. 1998. — Vol. 1. — P. 991−1000.
- Neumann G. and Kawaoka Y. Reverse genetics systems for the generation ofsegmented negative-sense RNA viruses entirely from cloned cDNA // Curr Top Microbiol Immunol. 2004. — Vol.283. — P. 43−60.
- Neumann G., Fujii K., Kino Y., Kawaoka Y. An improved reverse geneticssystem for influenza A virus generation and ist implications for vaccine production // Proc. Natl. Acad. Sci. USA. 2005. — P. 16 825 -16 829.
- Neumann G., Shinya K., Kawaoka Y. Molecular pathogenesis of H5N1 influenzavirus infections // Antivir Ther. 2007. — Vol.12. — P. 617−626.
- Neumann G., Watanabe T., Ito H. et al. Generation of influenza A viruses entirelyfrom cloned cDNAs // Proc Natl Acad Sci USA.- 1999. Vol. 96. — P. 93 459 350.
- Neumann G., Zobel A., Hobom G. RNA polymerase I-mediated expression ofinfluenza viral RNA molecules // Virology. 1994. — Vol.202(l). — P. 477−479.
- Newby C., Sabin L., Pekosz A. The RNA binding domain of influenza A virus
- NS1 protein affects secretion of tumor necrosis factor alpha, interleukin-6, and interferon in primary murine tracheal epithelial cells // J Virol. 2007. -Vol.81(17). — P. 9469−9480.
- Noah J., Severson W., Noah D. et al. A cell-based luminescence assay is effectivefor high-throughput screening of potential influenza antivirals // Antiviral Res. -2007. Vol.73(l).-P. 50−59.
- Olsen B., Munster V.J., Wallensten A. and Waldenstrom J. Global patterns ofinfluenza a virus in wild birds // Science. 2006. — Vol.312. — P. 384−388.
- Ono A. and Freed E.O. Role of lipid rafts in virus replication // Adv Virus Res.2005. Vol.64. — P. 311−358.
- Oster G., Weycker D., Edelsberg J. et al. Benefits and risks of live attenuatedinfluenza vaccine in young children // Am J Manag Care. 2010. — Vol. 16(9). -P. 543−457.
- Palache A.M., Brands R., van Scharrenburg G.J. Immunogenicity andreactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs // J Infect Dis. 1997. — Vol.176 Suppl 1. — P. S20−23.
- Palese P. and Garcia-Sastre A. Influenza vaccines: present and future // J Clin1.vest. 2002. — Vol.110(1). — P. 9−13.
- Palese P. and Shaw M.L. Orthomyxoviridae. The viruses and their replication //1.: Fields Virology 5th Edition. Rnippe DM, Howley PH (Eds). Lippincott Williams and Wilkins, PA, USA. 2007, — P. 1647−1689.
- Park C., Bae S., Lee M. et al. Solution structure of the influenza A virus cRNApromoter: implications for differential recognition of viral promoter structures by RNA-dependent RNA polymerase // Nucleic Acids Res. 2003. — Vol.31(11). — P. 2824−2832.
- Park Y. W. and Katze M. G. Translational control by influenza virus.1.entification of cis-acting sequences and trans-acting factors which may regulate selective viral mRNA translation // J Biol Chem. 1995. — V. 270. -P. 28 433−28 439.
- Pleschka S., Jaskunas R., Engelhardt O. G. et al. A plasmid-based reversegenetics system for influenza A virus // J Virol. 1996. -Vol. 70. — P. 41 884 192.
- Qian X. Y., Alonso-Caplen F. and Krug R. M. Two functional domains of theinfluenza virus NS1 protein are required for regulation of nuclear export of mRNA // J Virol. 1994. — Vol. 68. — P. 2433−2441.
- Qiu Y., Nemeroff M. and Krug R. M. The influenza virus NS1 protein binds to aspecific region in human U6 snRNA and inhibits U6-U2 and U6-U4 snRNA interactions during splicing // Rna. 1995. — Vol. 1. — P. 304−316.
- Quinlivan M., Zamarin D., Garcia-Sastre A. et al. Attenuation of equine influenzaviruses through truncations of the NS1 protein // J Virol. 2005. — Vol.79(13). -P. 8431−8439.
- Racaniello V. and Baltimore D. Molecular cloning of poliovirus cDNA anddetermination of the complete nucleotide sequence of the viral genome // Proc Natl Acad Sci USA. 1981. — Vol.78(8). — P. 4887−4891.
- Reid A.H., Taubenberger J.K. and Fanning T.G. Evidence of an absence: thegenetic origins of the 1918 pandemic influenza virus // Nat Rev Microbiol. -2004. Vol. 2. — P. 909−914.
- Richt J., Garcia-Sastre A. Attenuated influenza virus vaccines with modified NS1proteins // Curr Top Microbiol Immunol. 2009. — Vol.333. — P. 177−195.
- Rimmelzwaan G., Kuiken T., van Amerongen G. et al. Pathogenesis of influenza
- A (H5N1) virus infection in a primate model // J Virol. 2001. — Vol.75. — P. 6687−6691.
- Rogers G. and Paulson J. Receptor determinants of human and animal influenzavirus isolates: differences in receptor specificity of the H3 hemagglutinin based on species of origin//Virology. 1983. — Vol. l27(2). — P. 361−373.
- Rohm C., Zhou N., Suss J. et al. Characterization of a novel influenzahemagglutinin, HI5: criteria for determination of influenza A subtypes // Virology. 1996. — Vol.217(2). — P. 508−516.
- Romanova J., Krenn B., Wolschek M. et al. Preclinical evaluation of areplication-deficient intranasal DeltaNSl H5N1 influenza vaccine // PLoS One. 2009. — Vol.4(6). — e. 5984.
- Rudenko L., Desheva J., Korovkin S., Mironov A., Rekstin A., Grigorieva E.,
- Donina S., Gambaryan A., Katlinsky A. Safety and immunogenicity of liveattenuated influenza reassortant H5 vaccine (phase I-II clinical trials) // Influenza Other Respi Viruses. 2008. — Vol.2(6). — P. 203−209.
- Schroeder C., Heider H., Moncke-Buchner E. and Lin T.I. The influenza virusion channel and maturation cofactor M2 is a cholesterol-binding protein // Eur Biophys J. 2005. — Vol.34(1). — P. 52−66.
- Schultz-Cherry S., Dybdahl-Sissoko N., Neumann G. and Kawaoka Y., Hinshaw
- V.S. Influenza virus nsl protein induces apoptosis in cultured cells //J Virol. -2001. Vol.75(17). — P. 7875−7878.
- Shaw ML. and Palese P. Orthomyxoviridae: The viruses and their replication. In:
- Knipe, DM., editor. Fields Virology, vol.2. Philadelphia: Lippincott Williams & Wilkins. 2007. — p. 254.
- Shinya K., Ebina M., Yamada S. et al. Avian flu: influenza virus receptors in thehuman airway // Nature. 2006. — Vol.440. — P. 435−436.
- Smith G.J., Naipospos T.S., Nguyen T.D. and de Jong M.D. Evolution andadaptation of H5N1 influenza virus in avian and human hosts in Indonesia and Vietnam // Virology. 2006. — Vol. 70(11). — P. 7531−7541.
- Smith L., Wloch M., Ye M. et al. Phase 1 clinical trials of the safety andimmunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin // Vaccine. 2010. — Vol.28(13). — P. 2565−7252.
- Solorzano A., Webby R., Lager K., Janke B., Garcia-Sastre A., Richt J.A.
- Mutations in the NS1 protein of swine influenza virus impair anti-interferon activity and confer attenuation in pigs // J Virol. 2005. — Vol. 79(12). — P. 75 357 543.
- Stasakova J., Ferko B., Kittel C. et al. Influenza A mutant viruses with altered
- NS1 protein function provoke caspase-1 activation in primary human macrophages, resulting in fast apoptosis and release of high levels of interleukins lbeta and 18 // J Gen Virol. 2005. — Vol. 86. — P. 185−195.
- Steitz J., Wagner R., Bristol T. et al. Assessment of route of administration anddose escalation for an adenovirus-based influenza A Virus (H5N1) vaccine in chickens // Clin Vaccine Immunol. 2010. — Vol. l7(9). — P. 1467−1472.
- Suarez D. and Perdue M.L. Multiple alignment comparison of the non-structuralgenes of influenza A viruses // Virus Res. 1998. — Vol.54(1). — P. 59−69.
- Subbarao K., Klimov A., Katz J. and Regnery H. Characterization of an avianinfluenza A (H5N1) virus isolated from a child with a fatal respiratory illness// Science. 1998. — Vol. 279. — P. 393−396.
- Takeda M., Pekosz A., Shuck K. et al. Influenza a virus M2 ion channel activityis essential for efficient replication in tissue culture // J Virol. 2002. -Vol.76(3). — P. 1391−1399.
- Takizawa T., Ohashi K. and Nakanishi Y. Possible involvement of doublestranded RNA-activated protein kinase in cell death by influenza virus infection // J Virol. 1996. — V. 70. -P. 8128−8132.
- Talon J., Horvath C. M., Polley R. et al. Activation of interferon regulatoryfactor 3 is inhibited by the influenza A virus NS1 protein // J Virol. 2000. — V. 74. — P. 7989−7996.
- Tam J.S. Influenza A (H5N1) in Hong Kong: an overview // Vaccine. -2002,1. Vol.20 Suppl 2.-P.S77−81.
- Tamura S. and Kurata T. Defense mechanisms against influenza virus infection inthe respiratory tract mucosa // Jpn J Infect Dis. 2004. — Vol.57(6). — P. 236−247.
- Tao P., Luo M., Zhu D. et al. Virus-like particle vaccine comprised of the HA,
- NA, and Ml proteins of an avian isolated H5N1 influenza virus induces protective immunity against homologous and heterologous strains in mice // Viral Immunol. 2009. — Vol.22(4). — P. 273−281.
- Tran T.H., Nguyen T.L., Nguyen T.D. and Luong T.S. Avian influenza A (H5N1)in 10 patients in Vietnam // N Engl J Med. 2004. — Vol. 350. — P. 1179−1188.
- Treanor J.J., Campbell J.D., Zangwill K.M. and Rowe T. Safety andimmunogenicity of an inactivated subvirion influenza A (H5N1) vaccine// N Engl J Med. 2006. — Vol.354. — P. 1343−1351.
- Ungchusak K., Auewarakul P., Dowell S.F. and Kitphati R. Probable person-toperson transmission of avian influenza A (H5N1) // N Engl J Med. 2005. — Vol. 352. — P. 333−340.
- Van Kampen K., Shi Z., Gao P. et al. Safety and immunogenicity of adenovirusvectored nasal and epicutaneous influenza vaccines in humans // Vaccine. -2005.- Vol.23(8). P. 1029−1036.
- Varga Z.T., Ramos .1, Hai R. et al. The influenza virus protein PB1-F2 inhibitsthe induction of type i interferon at the level of the MAVS adaptor protein // PLoS Pathog. -2 011. Vol.7(6). — e. 1 002 067.
- Vincent A., Ma W., Lager K. et al. A. Efficacy of intranasal administration of atruncated NS1 modified live influenza virus vaccine in swine // Vaccine. 2007.- Vol.25(47). P. 7999−8009.
- Wacheck V., Egorov A., Groiss F. et al. A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1 //J. Infect. Dis. 2010. — Vol.201(3). -P. 354−362.
- Wang W. and Krug R. MU6atac snRNA, the highly divergent counterpart of U6snRNA, is the specific target that mediates inhibition of AT-AC splicing by the influenza virus NS1 protein // Rna. 1998. — Vol. 4. — P. 55−64.
- Wang X., Li M., Zheng H. et al. Influenza A virus NS1 protein preventsactivation of NF-kappaB and induction of alpha/beta interferon // J Virol. -2000. -Vol. 74. P. 11 566−11 573.
- Wathelet M. G., Lin C. H., Parekh B. S. et al. Virus infection induces theassembly of coordinately activated transcription factors on the IFN-beta enhancer in vivo // Mol Cell. 1998. mVoI. 1. — P. 507−518.
- Webster R., Bean W., Gorman O., Chambers T., Kawaoka Y. Evolution andecology of influenza A viruses // Microbiol Rev. 1992. — Vol.56(1). — P. 152 179.
- Wise H., Foeglein A., Sun J. et al. A complicated message: Identification of anovel PB1-related protein translated from influenza A virus segment 2 mRNA // J Virol. 2009. — Vol.83(16). — P. 8021−8031.
- Wressnigg N., Voss D., Wolff T. et al. Development of live-attenuated influenza
- B DeltaNS 1 intranasal vaccine candidate // Vaccine. 2009. — Vol.27. — P. 28 512 857.
- Yamada H., Chounan R., Higashi Y. et al. Mitochondrial targeting sequence ofthe influenza A virus PB1-F2 protein and its function in mitochondria // FEBS Lett. 2004. — Vol.578(3).- P. 331−336.
- Yang P., Tang C., Luo D. et al. Cross-clade protection against HPAI H5N1influenza virus challenge in BALB/c mice intranasally administered adjuvant-combined influenza vaccine//Vet Microbiol. 2010. — Vol. 146(1−2). — P. 17−23.
- Yasuda J., Bucher D., Ishihama A. Growth control of influenza A virus by Mlprotein: analysis of transfectant viruses carrying the chimeric M gene // J Virol.-1994. Vol.68(12). — P. 8141−8146.
- Yoshida T., Shaw M. W., Young J. F. and Compans R. W. Characterization ofthe RNA associated with influenza A cytoplasmic inclusions and the interaction of NS1 protein with RNA//Virology. 1981. — Vol. 110. — P. 87−97.
- Zamarin D., Garcia-Sastre A., Xiao X. et al. Influenza virus PB1-F2 proteininduces cell death through mitochondrial ANT3 and VDAC1 // PLoS Pathog. -2005. Vol. l (l).-e. 4.
- Zamarin D., Ortigoza M. and Palese P. Influenza A virus PB1-F2 proteincontributes to viral pathogenesis in mice // J Virol. 2006. — Vol.80(16). — P. 7976−7983.
- Zell R., Krumbholz A., Eitner A. et al. Prevalence of PB1-F2 of influenza Aviruses // J Gen Virol. 2007. — Vol.88. — P. 536−546.
- Zhirnov O., Konakova T., Wolff T. and Klenk H. NS1 protein of influenza A virus down-regulates apoptosis // J Virol. 2002. — Vol.76(4). — P. 1617−1625.